New Zealand Bans New Puberty Blocker Prescriptions for Kids With Gender Dysphoria

New Zealand has announced a ban on new prescriptions of puberty-blocking medication for young people with gender dysphoria, aligning the country with similar policy shifts in the UK, Sweden, Finland, and Norway.

The drugs—gonadotropin-releasing hormone analogues—will remain available to those who need to take them for conditions with established clinical evidence, including early-onset puberty, endometriosis, or prostate cancer.

New Zealander Health Minister Simeon Brown said the change, which takes effect on Dec. 19, is a precautionary measure while long-term evidence is reviewed internationally.

“These changes are about ensuring treatments are safe and carefully managed, while maintaining access to care for those who need it,” Brown said.

Existing patients already prescribed puberty blockers for gender dysphoria will be allowed to continue treatment.

Government Cites Evidence Gaps, Aligns With UK Review

Brown said the decision follows advice from the Ministry of Health and findings from the independent Cass Review in the UK, which identified “considerable uncertainty about the long-term safety and clinical effectiveness” of puberty blockers for gender dysphoria.

“This wasn’t a political review; it was clinical,” he said.

He added that similar safeguards overseas reflect a shift toward evidence-based caution rather than ideological debate.

New Zealand will prohibit the use of the medication to treat new patients for the condition until the completion of a clinical trial in the UK, expected in 2031.

Coalition Partners Claim Credit

New Zealand First leader Winston Peters said his party pushed for the policy during coalition negotiations.

“It is common sense to put a pause on these unproven and potentially damaging drugs for children until we assess the results of the clinical trial. Promise made. Promise kept,” he said on X.

“New Zealand First was the only party that campaigned around the country about stopping the use of puberty blockers in children, and we never stopped fighting to make this happen.”

ACT New Zealand party spokesperson Karen Chhour said medical transitions should not be a default pathway.

“Growing up can be challenging and confusing, but using puberty blockers as the primary treatment can cause lifelong effects that are later regretted,” she said.

“The world has rushed to put young people on a medical pathway without the evidence to show that it’s safe or effective.”

Critics Warn of Mental Health Impact

Green Party Member of Parliament Ricardo Menéndez March accused the government of “buying into imported culture wars.”

“We know from queer people that gender-affirming health care can be life-saving,” he said.

“The government should focus on addressing the core issues that our health system faces … rather than waging culture wars on trans people.”

The Professional Association for Transgender Health Aotearoa (PATHA) also condemned the decision, saying the ban was “ideologically driven.”

Dr. Elizabeth McElrea, vice president of PATHA, said the policy would “lead to a deterioration in mental health, increased risk of suicidality and increased dysphoria” among affected young people.

“The prescribing of puberty blockers is always undertaken with the utmost care and consideration,” she said.

“They have been prescribed safely for decades for transgender children, and banning their use will put them at a higher risk of experiencing marginalisation and discrimination.”

PATHA also disputes Brown’s claim that the Ministry of Health’s 2024 evidence brief supported the decision.

“While the evidence brief identified some limitations in the academic quality of evidence regarding the risks and benefits of [the treatment], limitations in evidence quality are common across a number of areas of medicine, especially within [pediatric] medicine, and do not justify a ban on access,” the group stated.

PATHA said the timing—NZ First publicly announcing the change before the formal statement—suggested political involvement in what it argued should be a clinical decision.

Global Shift Toward Evidence-Based Caution

The Cass Review concluded that evidence for gender-affirming medicine has been “remarkably weak,” with study results misrepresented by people on all sides of the debate, and recommended that the clinical trial be undertaken.

The move was hailed by well-known anti-transgender activists, including Billboard Chris, Sall Grover, and Graham Linehan, with the latter commenting that those who had opposed the therapy had been “smeared, harassed and bullied for a decade, yet still got this momentous result.”